Risk factors for relapse after discontinuation of tenofovir or entecavir in hepatitis B e antigen-negative patients

Basit Öğe Kaydı
dc.authoridMERMUTLUOGLU, CIGDEM/0000-0003-1836-6281
dc.contributor.authorMermutluoglu, Cigdem
dc.contributor.authorKarasahin, Omer
dc.contributor.authorCelen, Mustafa Kemal
dc.date.accessioned2025-02-22T14:08:48Z
dc.date.available2025-02-22T14:08:48Z
dc.date.issued2024
dc.departmentDicle Üniversitesien_US
dc.description.abstractBackground and Aim: This study aimed to define the relapse frequency and risk determinants in chronic hepatitis B (CHB) patients who discontinued nucleoside analog (NA) treatment, were HBeAg-negative, and had achieved both a virological and biochemical response. Materials and Methods: This retrospective cohort study reviewed patients with HBeAg-negative CHB who received antiviral therapy for at least 65 months between January 1, 2013, and December 31, 2020. These patients discontinued treatment after demonstrating a biochemical and virological response and were evaluated at 6, 12, and 24 months post-treatment discontinuation. Results: Sixty-seven patients with CHB who received NA therapy for at least 65 months, discontinued treatment, and had undetectable HBV DNA and normal ALT values were evaluated. After cessation of NA therapy, a relapse was observed in 38 patients (56.7%). The relapse rate was 71.0% in patients treated with tenofovir disoproxil fumarate (TDF) as the last NA type and 37.9% in patients treated with entecavir (ETV) (p=0.017). The cutoff value for the best estimate of age for predicting relapse was 42 years. The relapse rate was 69.2% in patients aged >42 years and 39.2% in patients aged <42 years (p=0.007). The relapse rate was 51.3% in patients with a pre-treatment fibrosis score of 2, 56.0% in those with a fibrosis score of 3, and 100% in those with a fibrosis score of 4 (p=0.089). Conclusion: Among HBeAg-negative CHB patients who achieved a virological and biochemical response to long-term antiviral therapy, those aged 42 years and older, those with high fibrosis scores before treatment, treatment.en_US
dc.identifier.doi10.14744/hf.2023.2023.0060
dc.identifier.endpage125en_US
dc.identifier.issn1307-5888
dc.identifier.issn2757-7392
dc.identifier.issue3en_US
dc.identifier.pmid39006145en_US
dc.identifier.scopus2-s2.0-85199194593en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage120en_US
dc.identifier.trdizinid1280158en_US
dc.identifier.urihttps://doi.org/10.14744/hf.2023.2023.0060
dc.identifier.urihttps://search.trdizin.gov.tr/tr/yayin/detay/1280158
dc.identifier.urihttps://hdl.handle.net/11468/29650
dc.identifier.volume5en_US
dc.identifier.wosWOS:001266321200005
dc.identifier.wosqualityN/A
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakTR-Dizin
dc.indekslendigikaynakPubMed
dc.language.isoenen_US
dc.publisherKare Publen_US
dc.relation.ispartofHepatology Forumen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.snmzKA_WOS_20250222
dc.subjectHepatitis Ben_US
dc.subjectdiscontinued treatmenten_US
dc.subjectrelapse.en_US
dc.titleRisk factors for relapse after discontinuation of tenofovir or entecavir in hepatitis B e antigen-negative patientsen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
TR-Dizin İndeksli Yayınlar Koleksiyonu